Risk Factors for Diabetes After Stem Cell Transplantation
NCT ID: NCT00539851
Last Updated: 2010-03-19
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
87 participants
OBSERVATIONAL
2005-11-30
2010-03-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Predicting Development of Diabetes Mellitus in Patients Undergoing Allogeneic Stem Cell Transplant
NCT02240381
Finding the Cause for Post-Transplant Diabetes Mellitus After Allogeneic Hematopoietic Cell Transplant
NCT03415139
The Prospective Collection, Storage and Reporting of Data on Patients Undergoing Hematopoietic Stem Cell Transplantation Utilizing a Standard Preparative Regimen
NCT01890486
Prevention of Graft-Versus-Host Disease in Patients Undergoing Bone Marrow Transplantation
NCT00003538
Mesenchymal Stem Cell Infusion as Prevention for Graft Rejection and Graft-versus-host Disease
NCT00504803
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
High dose corticosteroids remain one of the cornerstone therapies to treat acute GVHD. However, an association between corticosteroid therapy and the development of diabetes mellitus after solid organ transplantation has become widely recognized. Similarly, post transplant diabetes mellitus (PTDM) has been increasingly noted in the allogenic stem cell transplant population, however, to date, no systematic study has been completed to identify the incidence of PTDM and associated risk factors. We propose to investigate the incidence of PTDM as well as associated risk factors for the development of PTDM in patients undergoing allogenic stem cell transplantation.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Fulfills institutional criteria for and is scheduled to undergo an allogenic stem cell transplantation at VUMC
Exclusion Criteria
* Pre-existing diabetes mellitus
* Positive pregnancy test
* Unable to complete the conditioning regimen prior to stem cell transplantation
* Unable to give informed consent
18 Years
65 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Sanofi
INDUSTRY
Vanderbilt University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Vanderbilt University Medical Center
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Shubhada Jagasia, MD
Role: PRINCIPAL_INVESTIGATOR
Vanderbilt University Medical Center
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
#040639
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.